Skip to main content
. 2021 Mar 15;9:647527. doi: 10.3389/fcell.2021.647527

Figure 2.

Figure 2

miR-195-5p acts as a negative regulator for CCNE1 in TNBC. (A) MIRWALK, MIRTARBASE, and MIRDIP predicted potentially related microRNAs of CCNE1. (B–D) TCGA BRCA database showed miR-195-5p expression in TNBC samples as compared with luminal-type breast cancer or normal breast samples (B), miR-195-5p and CCNE1 expression correlation in TNBC (n = 113) (C), and 3-year overall survival in 100 patients with TNBC according to the miR-195-5p expression (D). (E,F) miR-195-5p expression in 30 human TNBC or 15 luminal-type breast cancer tissues and 45 adjacent normal breast tissues (E) and expression correlation with CCNE1 in 30 TNBC samples (F). (G) Expression of miR-195-5p in breast cancer cell lines and HBL-100. (H) Relative RNA levels of miR-195-5p were detected in cells after being transfected with miR-NC, miR-mimics, miR-Ctrl, and miR-inhibitor using qRT-PCR. (I) Schematic illustration of CCNE1 luciferase reporter vectors. (J) The relative luciferase activities were detected in SUM1315 cells after transfection. (K,L) Relative mRNA (K) and protein levels (L) of CCNE1 were detected in cells after being transfected with miR-NC, miR-mimics, miR-Ctrl, and miR-inhibitor. Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.